Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975 Aug;5(3):264-7.
doi: 10.1007/BF02026441.

Investigations on the influence of cyclophosphamide, gold sodium thiomalate and D-penicillamine on nystatin oedema and adjuvant arthritis

Investigations on the influence of cyclophosphamide, gold sodium thiomalate and D-penicillamine on nystatin oedema and adjuvant arthritis

E Arrigoni-Martelld et al. Agents Actions. 1975 Aug.

Abstract

Cyclophosphamide (5 or 10 mg/kg p.o.) and Gold sodium thiomalate (0 or 40 mg/kg i.m.) inhibit after repeated administrations (5 days) all the phases of Nystatin edema, whereas a single administration is ineffective. D-Penicillamine (25 or 100 mg/kg p.9.) inhibits the early phases of Nystatin edema after a single administration whereas repeated administrations are almost ineffective. An early treatment with Cyclophosphamide (2.5 mg/kg p.o.) simply delays the appearance of the secondary lesions of adjuvant arthritis but inhibit the development of the primary lesions. A late treatment with Cyclophosphamide as both the types of treatment with Gold sodium thiomalate (10 mg/kg i.m.) are effective against primary and secondary lesions. The only effect of D-Penicillamine (50 mg/kg p.o.) in adjuvant arthritis is a significant increase of the intensity of secondary lesions during the late treatment. It is suggested that the anti-inflammatory activity of Cyclophosphamide does not depend exclusively upon its immunosuppressant activity and that D-Penicillamine is effective on some cell population committed in the inflammatory reactions.

PubMed Disclaimer

References

    1. Ann Rheum Dis. 1972 Nov;31(6):521 - PubMed
    1. Arch Int Pharmacodyn Ther. 1970 Jan;183(1):1-11 - PubMed
    1. Arthritis Rheum. 1968 Dec;11(6):756-64 - PubMed
    1. Lancet. 1973 Feb 10;1(7798):275-80 - PubMed
    1. Br Med J. 1971 Feb 20;1(5746):460 - PubMed